Congress locks in NIH grants, shields research from political interference
H.R. 7173 — Follow the Science Act · Filed by Diana DeGette (D-CO) · 43 cosponsors · Introduced Jan 21, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill restricts political appointees from working at or influencing decisions within the National Institutes of Health (NIH), except for the NIH Director and two other top officials. It also prohibits the NIH from canceling or suspending grants and contracts unless the agency documents financial mismanagement, fraud, or debarment in writing and notifies Congress within 30 days. The bill requires a report on political appointees' past involvement in NIH activities since January 2021.
Why we flagged it
The bill's primary mechanism is twofold: (1) removing political appointees from NIH decision-making to protect research independence, and (2) restricting the NIH's ability to cancel grants without documented cause and congressional notice. The first is a governance/integrity measure; the second functions as a grant-protection constraint that may limit agency flexibility.
What the text implies
- The prohibition on grant cancellation without written findings of fraud/mismanagement may prevent the NIH from terminating agreements for policy misalignment, shifting research priorities, or failure to meet non-fraud performance standards—effectively locking in funding streams regardless of evolving public health needs.
- The 30-day congressional notification requirement for all cancellations/suspensions creates a de facto veto point: Congress could use the notice period to pressure the NIH to reverse terminations, even when scientifically justified.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical companies (Pfizer, Bristol Myers Squibb, Johnson & Johnson); healthcare service providers (DaVita); biotech and life sciences contractors receiving NIH grants and contracts